Sensor Enabled News Today

ADAGIO MEDICAL Investor Presentation | June 2024 1 DISCLAIMER This investor presentation is for informational purposes only to assist interested parties in making their...

/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Pulsed Field Ablation Market- By Therapeutic...

/PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2023....

/PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the companys TactiFlex™ Ablation Catheter,...

Abbott (ABT) announced the FDA has approved the company's TactiFlex Ablation Catheter, Sensor Enabled, an ablation catheter with a flexible tip and contact force technology.

North America to account for larger share in atrial fibrillation market during 2022–2028; growth driven by rising geriatric population, increasing occurrence of cardiovascular diseases, high accessibility to advanced technologies, growing development of innovative and technologically advanced products, and increasing healthcare expenditure

FlexAbility Ablation Catheter, Sensor Enabled secures FDA approval for an expanded indication following favorable study outcomes in treating complex heart condition 

Treatment with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ resulted in patients with persistent atrial fibrillation experienci...

/PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the PERSIST-END study, which showed that nearly nine out of 10 patients (89%) treated for...

Abbott announced today that a study showed its TactiCath ablation catheter often led to more than a year of freedom from AFib symptoms.